On September 14, 2020, our Phoenix laboratory began performing a portion of our alternate donor antibody screen on the Ortho Clinical Diagnostics VISION Analyzer. This instrumentation change was necessary as Ortho Clinical Diagnostics will be discontinuing support of the existing ProVue instrumentation in the future.
We will notify you of the transition date of our other four laboratories. To read more about this change, click here: Communications
CTS successfully implemented Donor-Screen HLA® Class I and II testing on the Stratec Biomedical ...
Celebrate National Blood Donor Month throughout January by inviting eligible individuals to donate b...
In response to the FDA guidance document for Babesia, CTS will implement the licensed Grifols ...
On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 conva...
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm. Th...
CTS will be revising some forms in use by clients on October 26, 2020. We do try to limit form chang...